8-K: Windtree Therapeutics Faces Nasdaq Delisting Risk Due to Non-Compliance and Low Share Price

Windtree Therapeutics has received notices from Nasdaq regarding non-compliance with board independence and audit committee rules, as well as a deficiency due to its stock price falling below the minimum bid price.

Summary

• Windtree Therapeutics has been notified by Nasdaq that it is not in compliance with the majority independent board standard and the audit committee composition standard.
• This non-compliance was triggered by the appointment of Jed Latkin as President and CEO, who was previously an independent director and audit committee member.
• The company has until the earlier of its next annual meeting or December 1, 2025, to regain compliance, with a potential deadline of May 30, 2025, if the annual meeting is before that date.
• Windtree also received a notice that its stock price has fallen below the minimum $1.00 per share required for continued listing.
• Due to two prior reverse stock splits, the company is not eligible for the standard 180-day compliance period.
• The company intends to request a hearing before a Nasdaq panel to seek an extension to regain compliance.
• There is no guarantee that the company will regain compliance with either the listing rules or the minimum bid price requirement.

Sentiment

Score: 3

Explanation: The document indicates significant negative developments for the company, including non-compliance with listing rules and a low stock price, which creates a high risk of delisting. This is a negative outlook for investors.

Positives

• The company is requesting a hearing with the Nasdaq panel which will automatically stay any suspension or delisting action.
• The company has a cure period to regain compliance with the board and audit committee rules.

Negatives

• The company is currently not in compliance with Nasdaq's majority independent board standard and audit committee composition standard.
• The company's stock price has fallen below the minimum bid price requirement.
• The company is not eligible for the standard 180-day compliance period for the minimum bid price rule.
• There is no assurance that the company will regain compliance with either the listing rules or the minimum bid price requirement.

Risks

• There is a risk that the company will be delisted from the Nasdaq Capital Market if it cannot regain compliance with listing rules.
• The company's stock price may be negatively impacted by the delisting risk.
• The company may face challenges in raising capital if it is delisted.
• The company's reputation may be damaged by the delisting risk.

Future Outlook

The company is reviewing options to regain compliance with Nasdaq listing requirements and intends to request a hearing to seek an extension to regain compliance with the minimum bid price rule. There is no assurance that the company will be successful in these efforts.

Management Comments

• The company is in the process of reviewing and evaluating potential options to regain compliance.
• The company intends to timely request a hearing before the Panel.

Industry Context

This announcement highlights the challenges faced by smaller biotech companies in maintaining compliance with listing requirements, particularly when facing financial pressures and leadership changes. It is not uncommon for companies in this sector to experience stock price volatility and struggle to meet minimum bid price requirements.

Comparison to Industry Standards

• Many small-cap biotech companies face similar challenges with Nasdaq listing requirements, particularly regarding minimum bid price and board independence.
• Companies like Athersys and Ocugen have also faced delisting risks due to low share prices, highlighting the common struggle in the sector.
• The use of reverse stock splits to regain compliance is a common strategy, but Windtree's prior use of this method limits its options for the current deficiency.

Management Changes

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment.
• Employees may experience uncertainty due to the company's financial and listing challenges.
• Creditors may be concerned about the company's ability to meet its obligations.

Next Steps

• The company will review and evaluate potential options to regain compliance with Nasdaq listing requirements.
• The company will request a hearing before a Nasdaq panel to seek an extension to regain compliance with the minimum bid price rule.

Key Dates

Keywords

Nasdaq, delisting, compliance, minimum bid price, independent board, audit committee, reverse stock split, hearing, WINT